Enteric Disease Testing Market Size worth $5,250.12 Million by 2032 | CAGR: 3.50%

The global Enteric Disease Testing Market is expected to grow at growth rate of 3.50% to reach USD 5,250.12 Million by 2032.

Enteric disease testing refers to the process of diagnosing infections that affect the gastrointestinal (GI) tract, typically caused by bacteria, viruses, or parasites. These infections are often transmitted through contaminated food or water, or via contact with infected people or animals. The primary goal of testing is to identify the exact pathogen responsible for symptoms such as diarrhea, vomiting, fever, and abdominal pain. Accurate identification enables healthcare providers to deliver targeted treatment, reduce the risk of complications, and help prevent the spread of the disease to others.

The Enteric Disease Testing market is undergoing significant growth, driven by the rising global incidence of gastrointestinal infections caused by bacteria, viruses, and parasites. These diseases are commonly associated with contaminated food and water, as well as poor sanitation conditions. According to the World Health Organization (WHO), diarrheal diseases remain the second leading cause of death among children under five, with many of these cases linked to enteric pathogens. Rapid urbanization, overcrowded living conditions, and uneven access to clean water are exacerbating the spread of these infections, increasing the demand for reliable diagnostic testing. In response, governments, NGOs, and international agencies are ramping up initiatives to improve food and water safety standards. Pathogens such as Salmonella, E. coli, and Listeria are frequent culprits in foodborne outbreaks, prompting stricter regulatory oversight and testing requirements. In the U.S., the Food Safety Modernization Act (FSMA) has been instrumental in mandating comprehensive safety protocols, leading to increased adoption of routine and rapid testing across the food and water supply chain. In 2023, the U.S. Food and Drug Administration (FDA) reported a rise in foodborne illness investigations, underscoring the growing need for advanced diagnostic solutions.

Request Sample Copy of Report: Enteric Disease Testing Market

The market is also benefiting from a shift away from traditional stool cultures toward cutting-edge molecular diagnostics, including Polymerase Chain Reaction (PCR), Nucleic Acid Amplification Tests (NAATs), and Next-Generation Sequencing (NGS). These technologies offer greater speed, accuracy, and sensitivity, enabling quicker identification of pathogens and more effective outbreak responses. As a result, technological innovation is playing a critical role in driving market expansion and strengthening global public health preparedness.

The Enteric Disease Testing market has a global presence, spanning North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. North America, especially the United States, holds a significant share of the market, driven by a well-established healthcare infrastructure, high awareness of enteric diseases, and the availability of advanced diagnostic technologies. In 2023, the U.S. Centers for Disease Control and Prevention (CDC) reported that over 48 million Americans suffered from foodborne illnesses, underscoring the persistent need for effective enteric disease testing solutions. Asia Pacific is expected to experience the fastest growth in the enteric disease testing market, fueled by an increasing number of waterborne and foodborne illnesses, particularly in densely populated regions grappling with urbanization and sanitation challenges. Inadequate infrastructure and poor sanitation in certain areas have contributed to a rise in infections. The World Health Organization (WHO) highlighted that waterborne diseases account for over 80% of enteric disease outbreaks in developing countries, emphasizing the demand for affordable and rapid testing solutions, particularly in rural areas. Additionally, ongoing investments in healthcare infrastructure and NGO-led initiatives focused on improving disease management are further supporting market growth in this region.

KEY BENEFITS OF THE REPORT:

• Insights into strategies adopted by key players to maintain competitiveness.
• Comprehensive analysis of the leading companies shaping the competitive landscape.
• Examination of the key drivers fuelling global market growth.
• Identification of the geographic regions expected to experience the highest growth.
• Detailed evaluation of the current market conditions and future growth projections.

The enteric disease diagnostics market is highly competitive, with companies concentrating on technological advancements, rapid diagnostics, and the development of multiplex testing panels. Multiplex panels are gaining traction as they replace traditional culture methods, enabling a single test to detect multiple pathogens at once. This innovation reduces testing time, improves diagnostic accuracy, and increases diagnostic yield. To expand their market presence, companies are increasingly investing in emerging markets such as India, Brazil, and several African countries to bolster healthcare infrastructure. These regions, which face high burdens of enteric diseases, present significant opportunities for growth and expansion in the diagnostics sector. Additionally, market players are actively focusing on new product launches and continuous innovation to improve the speed and efficiency of diagnostics. These efforts aim to enhance the ability to quickly identify pathogens, enabling more effective and timely treatment interventions and playing a crucial role in reducing the spread of enteric diseases globally.

Market Segmentation

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ENTERIC DISEASE TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• BioMérieux
• BD (Becton, Dickinson and Company)
• Thermo Fisher Scientific
• Roche Diagnostics
• Abbott Laboratories
• QIAGEN
• DiaSorin
• Meridian Bioscience
• Hologic Inc.
• Cepheid
• Siemens Healthineers
• Danaher Corporation
• Agilent Technologies
• Merck KGaA
• Intertek
• Bio-Rad Laboratories
• Others

GLOBAL ENTERIC DISEASE TESTING MARKET, BY TESTING- MARKET ANALYSIS, 2019-2032

• Rapid
• Traditional
• PCR
• Immunoassay
• Chromatography

GLOBAL ENTERIC DISEASE TESTING MARKET, BY DISEASE- MARKET ANALYSIS, 2019-2032

• Bacterial
• Viral
• Parasitic

GLOBAL ENTERIC DISEASE TESTING MARKET, BY END USE- MARKET ANALYSIS, 2019-2032

• Water
• Food

GLOBAL ENTERIC DISEASE TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM

The Middle East and Africa

• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA